| Date | Time | Source | Headline | Symbol | Company |
| 04/22/2024 | 12:49PM | iHub Newswire | FeaturedCannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California | | |
| 04/23/2024 | 1:27AM | Alliance News |  Moderna, Pfizer/BioNTech set for UK court clash over Covid jab patents | LSE:0A45 | Moderna Inc |
| 04/23/2024 | 1:27AM | Alliance News | Moderna, Pfizer/BioNTech set for UK court clash over Covid jab patents | LSE:0Q1N | Pfizer Inc |
| 04/23/2024 | 1:27AM | Alliance News | TOP NEWS: Japan business activity growth quickens as orders pick up | | |
| 04/23/2024 | 1:25AM | PR Newswire (US) | SASOL LIMITED: PRODUCTION AND SALES METRICS FOR THE NINE MONTHS ENDED 31 MARCH 2024 | NYSE:SSL | Sasol Ltd |
| 04/23/2024 | 1:22AM | GlobeNewswire Inc. | Earth Day 2024: Coherent Corp. Announces Milestones in its Sustainability Journey | NYSE:COHR | Coherent Corp |
| 04/23/2024 | 1:16AM | PR Newswire (US) | Envision Energy Explores the Future of Green Hydrogen Fuel Adoption at Singapore Maritime Week | | |
| 04/23/2024 | 1:14AM | PR Newswire (US) | Largest Chinese Trade Delegation in Years Secures Cooperative Intentions in New Zealand | | |
| 04/23/2024 | 1:10AM | PR Newswire (US) | Envision Energy Explores the Future of Green Hydrogen Fuel Adoption at Singapore Maritime Week | | |
| 04/23/2024 | 1:06AM | PR Newswire (US) | Electroceuticals/Bioelectric Medicine Market to Reach $40.5 Billion, Globally, by 2032 at 7.4% CAGR: Allied Market Research | | |
| 04/23/2024 | 1:05AM | PR Newswire (Canada) | Largest Chinese Trade Delegation in Years Secures Cooperative Intentions in New Zealand | | |
| 04/23/2024 | 1:05AM | PR Newswire (US) | Largest Chinese Trade Delegation in Years Secures Cooperative Intentions in New Zealand | | |
| 04/23/2024 | 1:05AM | GlobeNewswire Inc. | EfTEN United Property Fund distributes approximately 260 000 euros to investors | | |
| 04/23/2024 | 1:01AM | PR Newswire (US) | Electroceuticals/Bioelectric Medicine Market to Reach $40.5 Billion, Globally, by 2032 at 7.4% CAGR: Allied Market Research | | |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Pico Launches Machine Learning and AI Capabilities in Corvil Analytics 10.0 Software Release | | |
| 04/23/2024 | 1:00AM | Business Wire | BenevolentAI Provides an Update on Its Business Priorities | | |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Renault Group : Chiffre d’affaires Groupe du 1er trimestre 2024 à 11,7 milliards d’euros, +5,9 % à taux de change constants ; dans les starting-blocks pour l'offensive produits à venir | EU:RNO | Renault SA |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Renault Group: 2024 Q1 Group revenue at €11.7 billion, +5.9% at constant exchange rate; in the starting-blocks for the upcoming product offensive | BIT:1RNO | Renault SA |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Renault Group: 2024 Q1 Group revenue at €11.7 billion, +5.9% at constant exchange rate; in the starting-blocks for the upcoming product offensive | EU:RNO | Renault SA |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire | TG:SNW | Sanofi |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia | EU:SAN | Sanofi |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Renault Group : Chiffre d’affaires Groupe du 1er trimestre 2024 à 11,7 milliards d’euros, +5,9 % à taux de change constants ; dans les starting-blocks pour l'offensive produits à venir | BIT:1RNO | Renault SA |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire | BIT:1SAN | Sanofi |
| 04/23/2024 | 1:00AM | Business Wire | KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma | NYSE:KKR | KKR and Company Inc |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia | TG:SNW | Sanofi |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia | EU:SAN | Sanofi |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire | EU:SAN | Sanofi |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia | BIT:SANF | Sanofi |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire | BIT:SANF | Sanofi |
| 04/23/2024 | 1:00AM | GlobeNewswire Inc. | Renault Group: 2024 Q1 Group revenue at €11.7 billion, +5.9% at constant exchange rate; in the starting-blocks for the upcoming product offensive | TG:RNL | Renault SA |